Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices

Transfusion

Volumn 54, Issue 5, 2014, Pages 1418-1437

  Sharma, Ratti Ram ^a   Pollock, Kathryn ^b   Hubel, Allison ^b   McKenna, David ^c  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DENSITY; CELL DIFFERENTIATION; CELL ISOLATION; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLONOGENESIS; CRYOPRESERVATION; CULTURE MEDIUM; GENOMIC INSTABILITY; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; NONHUMAN; OXYGEN TENSION; QUALITY CONTROL; REVIEW; SENESCENCE; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; STORAGE; TISSUE REPAIR;

CELL SEPARATION; CLINICAL TRIALS AS TOPIC; FETAL BLOOD; GENOMIC INSTABILITY; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HUMANS; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; QUALITY CONTROL; REGENERATION;

EID: 84900517225     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12421     Document Type: Review

References (187)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230-247.
2. Zuk PA, Zuh M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279-4295. (Pubitemid 35471185)
3. In't Anker PS, Scherjon SA, Kleijburg-van Dder Keur C, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 2004; 22: 1338-1345. (Pubitemid 39636409)
4. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-1416. (Pubitemid 41541969)
5. Kern S, Eichler H, Stoeve J, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301. (Pubitemid 44464698)
6. Bochev I, Elmadjian G, Kyurkchiev D, et al. Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol Int 2008; 32: 384-393.
7. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317. (Pubitemid 44269669)
8. Haniffa MA, Collin MP, Buckley CD, et al. Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 2009; 94: 258-263.
9. Wang S, Qu X, Zhao RC,. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012; 5: 19.
10. Otto WR, Wright NA,. Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair 2011; 4: 20.
11. Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells: implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557-564.
12. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6: 1282-1286.
13. Popp FC, Eggenhofer E, Renner P, et al. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transpl Immunol 2008; 20: 55-60.
14. Tse WT, Pendleton JD, Beyer WM, et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397. (Pubitemid 36222968)
15. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
16. Nasef A, Mathieu N, Chapel A, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84: 231-237. (Pubitemid 47205757)
17. Sundin M, Ringden O, Sundberg B, et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007; 92: 1208-1215. (Pubitemid 350144179)
18. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843. (Pubitemid 34534559)
19. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13: 263-271. (Pubitemid 38738368)
20. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113: 46-57.
21. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372. (Pubitemid 43053565)
22. Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37: 604-615.
23. Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490. (Pubitemid 43242385)
24. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
25. English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
26. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 2010; 138: 965-972.
27. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001. (Pubitemid 36857986)
28. Phinney DG, Prockop DJ,. Concise review: mesenchymal stem / multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007; 25: 2896-2902. (Pubitemid 350127874)
29. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441. (Pubitemid 38586721)
30. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008; 371: 1579-1586. (Pubitemid 351626841)
31. Pérez-Simon JA, Lõpez-Villar O, Andreu EJ, et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011; 96: 1072-1076.
32. Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: A phase 1 study. Int J Hematol 2012; 95: 182-188.
33. Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011; 17: 534-541.
34. Arima N, Nakamura F, Fukunaga A, et al. Single intra-Arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: A pilot study. Cytotherapy 2010; 12: 265-268.
35. Zhang LS, Liu QF, Huang K, et al. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease]. Zonghua Nei Ke Za Zhi 2009; 48: 542-546.
36. Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010; 16: 403-412.
37. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 804-811.
38. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397. (Pubitemid 43847148)
39. Hou RQ, Wang J, Kong Y, et al. Transfusion of mesenchymal stem cells combined with haploidentical HSCT improves hematopoietic microenvironment. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18: 155-160.
40. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838-847.
41. Zhang X, Li JY, Cao K, et al. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases. Int J Lab Hematol 2010; 32: 256-264.
42. Wu T, Bai H, Wang CB, et al. Autologous bone marrow-derived mesenchymal stem cells and peripheral blood stem cells cotransplantation in treatment of hematological malignant diseases. Zhonghua Nei Ke Za Zhi 2009; 48: 392-395.
43. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22: 593-599. (Pubitemid 351386730)
44. MacMillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009; 43: 447-454.
45. Müller I, Kordowich S, Holzwarth C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008; 40: 25-32. (Pubitemid 350199635)
46. Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764-2767. (Pubitemid 47523204)
47. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398. (Pubitemid 40542932)
48. Koç ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307-316. (Pubitemid 30056419)
49. Meuleman N, Tondreau T, Ahmad I, et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: A pilot study. Stem Cells Dev 2009; 18: 1247-1252.
50. Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells Dev 2011; 20: 1679-1685.
51. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305-2315.
52. Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: A pilot clinical study. Ann Rheum Dis 2010; 69: 1423-1429.
53. Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432.
54. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012; 307: 1169-1177.
55. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: A pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6: 412-422.
56. Yamout B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010; 227: 185-189.
57. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4: 50-57. (Pubitemid 46799666)
58. Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72: 32-40.
59. Lee PH, Kim JW, Bang OY, et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008; 83: 723-730. (Pubitemid 351556019)
60. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11: 150-156.
61. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. (Pubitemid 29282067)
62. Meuleman N, Tondreau T, Delforge A, et al. Human marrow mesenchymal stem cell culture: serum-free medium allows better expansion than classical alpha-MEM medium. Eur J Haematol 2006; 76: 309-316. (Pubitemid 43362939)
63. Capelli C, Domenghini M, Borleri G, et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007; 40: 785-791. (Pubitemid 47521539)
64. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100: 8407-8411. (Pubitemid 36842558)
65. Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008; 15: 730-738. (Pubitemid 351627356)
66. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667-679.
67. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-49. (Pubitemid 34742565)
68. Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004; 103: 1669-1675. (Pubitemid 38268958)
69. Tomita Y, Makino S, Hakuno D, et al. Application of mesenchymal stem cell derived cardiomyocytes as bio-pacemakers: current status and problems to be solved. Med Biol Eng Comput 2007; 45: 209-220. (Pubitemid 46291445)
70. Bianco P, Cao X, Frenette PS, et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 2013; 19: 35-42.
71. Gojo S, Gojo N, Takeda Y, et al. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res 2003; 288: 51-59. (Pubitemid 36870997)
72. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108: 863-868. (Pubitemid 37022130)
73. Psaltis PJ, Zannettino AC, Worthley SG, et al. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008; 26: 2201-2210.
74. Petrie Aronin CE, Tuan RS,. Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells. Birth Defects Res C Embryo Today 2010; 90: 67-74.
75. Ankrum J, Karp JM,. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
76. Dennis JE, Merriam A, Awadallah A, et al. A quadri-potential mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res 1999; 14: 700-709. (Pubitemid 29210596)
77. Plotnikov EY, Khryapenkova TG, Vasileva AK, et al. Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. J Cell Mol Med 2008; 12: 1622-1631.
78. Cselenyak A, Pankotai E, Horvath EM, et al. Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections. BMC Cell Biol 2010; 11: 29.
79. Van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-1643. (Pubitemid 351702746)
80. Miettinen JA, Salonen RJ, Ylitalo K, et al. The effect of bone marrow microenvironment on the functional properties of the therapeutic bone marrow-derived cells in patients with acute myocardial infarction. J Transl Med 2012; 10: 66.
81. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277-2286.
82. Yang Z, Zhang F, Ma W, et al. A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery. Cardiovasc Ther 2010; 28: 380-385.
83. Chen SL, Fang WW, Qian J, et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004; 117: 1443-1448. (Pubitemid 39530218)
84. Mohyeddin-Bonab M, Mohamad-Hassani MR, Alimoghaddam K, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch Iran Med 2007; 10: 467-473. (Pubitemid 350001897)
85. Katritsis DG, Sotiropoulou PA, Karvouni E, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65: 321-329. (Pubitemid 40898172)
86. Friis T, Haack-Sørensen M, Mathiasen AB, et al. Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand Cardiovasc J 2011; 45: 161-168.
87. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011; 108: 792-796.
88. Guhathakurta S, Subramanyan UR, Balasundari R, et al. Stem cell experiments and initial clinical trial of cellular cardiomyoplasty. Asian Cardiovasc Thorac Ann 2009; 17: 581-586.
89. Chen S, Liu Z, Tian N, et al. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18: 552-556. (Pubitemid 44704523)
90. Wang JA, Xie XJ, He H, et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 107-110.
91. Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol 2012; 27 (Suppl 2): 112-120.
92. Amer ME, El-Sayed SZ, El-Kheir WA, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol 2011; 23: 936-941.
93. Kharaziha P, Hellström PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-1205.
94. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med 2007; 10: 459-466. (Pubitemid 350001896)
95. Lu D, Chen B, Liang Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011; 92: 26-36.
96. Lasala GP, Silva JA, Gardner PA, et al. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 2010; 61: 551-556.
97. Dash NR, Dash SN, Routray P, et al. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009; 12: 359-366.
98. Falanga V, Iwamoto S, Chartier M, et al. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007; 13: 1299-1312. (Pubitemid 46986730)
99. Honmou O, Houkin K, Matsunaga T, et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011; 134 (Pt 6): 1790-1807.
100. Lee JS, Hong JM, Moon GJ, et al.; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28: 1099-1106.
101. Bang OY, Lee JS, Lee PH, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874-882. (Pubitemid 40798626)
102. Pal R, Venkataramana NK, Bansal A, et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: A pilot clinical study. Cytotherapy 2009; 11: 897-911.
103. Davatchi F, Abdollahi BS, Mohyeddin M, et al. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011; 14: 211-215.
104. Chang T, Tang K, Tao X, et al. Treatment of early avascular necrosis of femoral head by core decompression combined with autologous bone marrow mesenchymal stem cells transplantation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2010; 24: 739-743.
105. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011; 5: 146-150.
106. Meijer GJ, de Bruijn JD, Koole R, et al. Cell based bone tissue engineering in jaw defects. Biomaterials 2008; 29: 3053-3061.
107. Koç ON, Day J, Nieder M, et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215-222. (Pubitemid 35023593)
108. Bartmann C, Rohde E, Schallmoser K, et al. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007; 47: 1426-1435. (Pubitemid 47101059)
109. Wexler SA, Donaldson C, Denning-Kendall P, et al. Adult bone marrow is a rich source of human mesenchymal "stem" cells but umbilical cord and mobilized adult blood are not. Br J Haematol 2003; 121: 368-374. (Pubitemid 36560606)
110. Kim S, Honmou O, Kato K, et al. Neural differentiation potential of peripheral blood- and bone-marrow-derived precursor cells. Brain Res 2006; 1123: 27-33.
111. Venkataramana NK, Kumar SK, Balaraju S, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 2010; 155: 62-70.
112. Centeno CJ, Busse D, Kisiday J, et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician 2008; 11: 343-353. (Pubitemid 351959424)
113. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20. (Pubitemid 38019084)
114. Pamphilon DH, Zbigniew M,. Szczepiorkowski. Regulation and accreditation in cellular therapy. In:, Murphy MF, Pamphilon DH, editors. Practical transfusion medicine. 3rd ed. West Sussex, UK: Wiley-Blackwell; 2009. p. 409-420.
115. Rohde E, Schallmoser K, Bartmann C, et al. GMP-compliant propagation of human multipotent mesenchymal stromal cells. In:, Gad SC, editor. Pharmaceutical manufacturing handbook: regulations and quality. Hoboken (NJ): John Wiley and Sons; 2008. p. 97-115.
116. Sensebé L, Bourin P, Tarte K,. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 2011; 22: 19-26.
117. Baxter MA, Wynn RF, Jowitt SN, et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004; 22: 675-682. (Pubitemid 39172200)
118. Stolzing A, Jones E, McGonagle D, et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008; 129: 163-173.
119. Bain BJ,. Bone marrow aspiration. J Clin Pathol 2001; 54: 657-663. (Pubitemid 32835409)
120. Guo KT, Schaefer R, Paul A, et al. A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 2006; 24: 2220-2231. (Pubitemid 44527475)
121. Gentry T, Foster S, Winstead L, et al. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy 2007; 9: 259-274. (Pubitemid 46705866)
122. Sorrentino A, Ferracin M, Castelli G, et al. Isolation and characterization of CD146(+) multipotent mesenchymal stromal cells. Exp Hematol 2008; 36: 1035-1046.
123. Caplan AI,. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007; 213: 341-347. (Pubitemid 47509711)
124. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006; 91: 1017-1026.
125. Caplan AI,. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318-324.
126. Schaffler A, Buchler C,. Concise review: Adipose tissue- derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25: 818-827. (Pubitemid 46572577)
127. Moseley TA, Zhu M, Hedrick MH,. Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg 2006; 118 (suppl 3): 121S-128. (Pubitemid 44319097)
128. Gimble JM, Katz AJ, Bunnell BA,. Adipose-derived stem cells for regenerative medicine. Circ Res 2007; 100: 1249-1260. (Pubitemid 46742916)
129. Oedayrajsingh-Varma MJ, van Ham SM, Knippenberg M, et al. Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy 2006; 8: 166-177. (Pubitemid 43675203)
130. Dubois SG, Floyd EZ, Zvonic S, et al. Isolation of human adipose-derived stem cells from biopsies and liposuction specimens. Methods Mol Biol 2008; 449: 69-79.
131. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-228. (Pubitemid 32295155)
132. Katz AJ, Hedrick MH, Llull R, et al. A novel device for the simple and efficient refinement of liposuctioned tissue. Plast Reconstr Surg 2001; 107: 595-597. (Pubitemid 32125311)
133. Duckers HJ, Pinkernell K, Milstein AM, et al. The Bedside Celution™ system for isolation of adipose derived regenerative cells. EuroIntervention 2006; 2: 395-398.
134. DiMuzio P, Tulenko T,. Tissue engineering applications to vascular bypass graft development: the use of adipose-derived stem cells. J Vasc Surg 2007; 45 (suppl A): A99-103. 395-398.
135. Bieback K, Kern S, Klüter H, et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004; 22: 625-634. (Pubitemid 39014578)
136. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-1337.
137. Sekiya I, Larson BL, Smith JR, et al. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002; 20: 530-541. (Pubitemid 35463066)
138. Both SK, van der Muijsenberg AJ, van Blitterswijk CA, et al. A rapid and efficient method for expansion of human mesenchymal stem cells. Tissue Eng 2007; 13: 3-9. (Pubitemid 46175525)
139. Sotiropoulou PA, Perez SA, Salagianni M, et al. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006; 24: 462-471. (Pubitemid 44464816)
140. Jaiswal N, Haynesworth SE, Caplan AI, et al. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem 1997; 64: 295-312. (Pubitemid 27065443)
141. Caterson EJ, Nesti LJ, Danielson KG, et al. Human marrow-derived mesenchymal progenitor cells: isolation, culture expansion, and analysis of differentiation. Mol Biotechnol 2002; 20: 245-256. (Pubitemid 34252636)
142. Asher DM,. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies. Dev Biol Stand 1999; 99: 41-44.
143. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products. EMEA CPMP/BWP/1793/02; 2003.
144. European Agency for the Evaluation of Medicinal Products. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. EMEA/410/01 rev3; 2011.
145. Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004; 9: 747-756. (Pubitemid 38660428)
146. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002; 99: 8932-8937. (Pubitemid 34693661)
147. Mannello F, Tonti GA,. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or adhoc formula? All that glitters is not gold! Stem Cells 2007; 25: 1603-1609. (Pubitemid 47121836)
148. Gruber R, Varga F, Fischer MB, et al. Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res 2002; 13: 529-535. (Pubitemid 41713080)
149. Graziani F, Ivanovski S, Cei S, et al. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 2006; 17: 212-219. (Pubitemid 43374309)
150. Lucarelli E, Beccheroni A, Donati D, et al. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials 2003; 24: 3095-3100. (Pubitemid 36944940)
151. Kilian O, Flesch I, Wenisch S, et al. Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. Eur J Med Res 2004; 9: 337-344.
152. Marx RE, Carlson ER, Eichstaedt RM, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 638-646. (Pubitemid 128641964)
153. Lucarelli E, Fini M, Beccheroni A, et al. Stromal stem cells and platelet-rich plasma improve bone allograft integration. Clin Orthop Relat Res 2005; 435: 62-68. (Pubitemid 40798647)
154. Bieback K, Hecker A, Kocaömer A, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009; 27: 2331-2341.
155. Kocaoemer A, Kern S, Kluter H, et al. Human AB serum and thrombin-Activated plateletrich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007; 25: 1270-1278. (Pubitemid 46684887)
156. Yamaguchi M, Hirayama F, Wakamoto S, et al. Bone marrow stromal cells prepared using AB serum and bFGF for hematopoietic stem cells expansion. Transfusion 2002; 42: 921-927.
157. Anselme K, Broux O, Noel B, et al. In vitro control of human bone marrow stromal cells for bone tissue engineering. Tissue Eng 2002; 8: 941-953. (Pubitemid 35397240)
158. Le Blanc K, Samuelsson H, Lonnies L, et al. Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation 2007; 84: 1055-1059. (Pubitemid 350287388)
159. Shahdadfar A, Fronsdal K, Haug T, et al. In vitro expansion of human mesenchymal stem cells: choice of serum is a determinant of cell proliferation, differentiation, gene expression and transcriptome stability. Stem Cells 2005; 23: 1357-1366. (Pubitemid 41504923)
160. Gregory CA, Reyes E, Whitney MJ, et al. Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs. Stem Cells 2006; 24: 2232-2243. (Pubitemid 44527476)
161. Kratchmarova I, Blagoev B, Haack-Sorensen M, et al. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005; 308: 1472-1477. (Pubitemid 40791302)
162. Ng F, Boucher S, Koh S, et al. PDGF, TGF-b and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSC into adipogenic, chondrogenic and osteogenic lineages. Blood 2008; 112: 295-307.
163. Tsutsumi S, Shimazu A, Miyazaki K, et al. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun 2001; 288: 413-419. (Pubitemid 33022499)
164. Kogler G, Sensken S, Wernet P,. Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Exp Hematol 2006; 34: 1589-1595. (Pubitemid 44548121)
165. De Boer J, Wang HJ, Van Blitterswijk C,. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng 2004; 10: 393-401. (Pubitemid 38580260)
166. Ebert R, Ulmer M, Zeck S, et al. Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells 2006; 24: 1226-1235. (Pubitemid 44464691)
167. Stolzing A, Coleman N, Scutt A,. Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res 2006; 9: 31-35.
168. Li YM, Schilling T, Benisch P, et al. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem Biophys Res Commun 2007; 363: 209-215. (Pubitemid 47430115)
169. Colter DC, Sekiya I, Prockop DJ,. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci U S A 2001; 98: 7841-7845. (Pubitemid 32642648)
170. Banfi A, Muraglia A, Dozin B, et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp Hematol 2000; 28: 707-715. (Pubitemid 30398528)
171. Prockop DJ, Brenner M, Fibbe WE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010; 12: 576-578.
172. Skmoser K, Rohde E, Reinisch A, et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 2008; 14: 185-196.
173. Sensebé L,. Clinical grade production of mesenchymal stem cells. Biomed Mater Eng 2008; 18: S3-S10. (Pubitemid 351366856)
174. Chen X, Xu H, Wan C, et al. Bioreactor expansion of human adult bone marrow-derived mesenchymal stemcells. Stem Cells 2006; 24: 2052-2059. (Pubitemid 44477130)
175. Gastens MH, Goltry K, Prohaska W, et al. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy. Cell Transplant 2007; 16: 685-696. (Pubitemid 351448264)
176. Rojewski M, Dausend J, Schmidtke-Schrezenmeier G, et al. A standardized protocol for GMP compliant expansion of MSC from BM in an animal component free system. Vox Sang 2010; 99: 43.
177. Grayson WL, Zhao F, Izadpanah R, et al. Effects of hypoxia on human mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell Physiol 2006; 207: 331-339.
178. Berniakovich I, Giorgio M,. Low oxygen tension maintains multipotency, whereas normoxia increases differentiation of mouse bone marrow stromal cells. Int J Mol Sci 2013; 14: 2119-2134.
179. McGuigan D,. Current news releases. Source: December 21; Stemedica Cell Technologies, Inc. Dec 12, 2012. [cited 2012 Dec 27]. Available from: http://www.stemedica.com.
180. Hanna J, Hubel A,. Preservation of stem cells. Organogenesis 2009; 5: 134-137.
181. Munson TE,. Guideline for validation of the LAL test as an end-product endotoxin test for human and biological products. Prog Clin Biol Res 1985; 189: 211-220.
182. Bifari F, Lisi V, Mimiola E, et al. Immune modulation by mesenchymal stem cells. Transfus Med Hemother 2008; 35: 194-204.
183. Kim J, Kang JW, Park JH, et al. Biological characterization of long-term cultured human mesenchymal stem cells. Arch Pharm Res 2009; 32: 117-126.
184. Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: A continuous and organized process. PloS One 2008; 3: e2213.
185. Tarte K, Gaillard J, Lataillade JJ, et al.; Société Française de Greffe de Moelle et Thérapie Cellulaire. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115: 1549-1553.
186. Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974; 2: 83-92.
187. Schallmoser K, Rohde E, Reinisch A, et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 2008; 14: 185-196.